Details
Stereochemistry | ACHIRAL |
Molecular Formula | C18H18Cl2N2O3 |
Molecular Weight | 381.253 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
COC1=C(OC2CCCC2)C=C(C=C1)C(=O)NC3=C(Cl)C=NC=C3Cl
InChI
InChIKey=RRRUXBQSQLKHEL-UHFFFAOYSA-N
InChI=1S/C18H18Cl2N2O3/c1-24-15-7-6-11(8-16(15)25-12-4-2-3-5-12)18(23)22-17-13(19)9-21-10-14(17)20/h6-10,12H,2-5H2,1H3,(H,21,22,23)
Molecular Formula | C18H18Cl2N2O3 |
Molecular Weight | 381.253 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: https://newdrugapprovals.org/2014/03/19/piclamilast/Curator's Comment: description was created based on several sources, including:
http://adisinsight.springer.com/drugs/800004110
http://www.drugbank.ca/drugs/DB01791
https://www.ncbi.nlm.nih.gov/pubmed/7613200
https://www.ncbi.nlm.nih.gov/pubmed/9316851
Sources: https://newdrugapprovals.org/2014/03/19/piclamilast/
Curator's Comment: description was created based on several sources, including:
http://adisinsight.springer.com/drugs/800004110
http://www.drugbank.ca/drugs/DB01791
https://www.ncbi.nlm.nih.gov/pubmed/7613200
https://www.ncbi.nlm.nih.gov/pubmed/9316851
Piclamilast (RP 73401), is a selective PDE4 inhibitor. It is comparable to other PDE4 inhibitors for its anti-inflammatory effects. It has been investigated for its applications to the treatment of conditions such as asthma, dermatitis, rheumatoid arthritis. Emesis is the most commonly cited side effect of piclamilast.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL275 Sources: https://www.ncbi.nlm.nih.gov/pubmed/15576036 |
0.041 nM [IC50] | ||
Target ID: CHEMBL288 Sources: https://www.ncbi.nlm.nih.gov/pubmed/15576036 |
0.021 nM [IC50] | ||
Target ID: CHEMBL254 Sources: https://www.ncbi.nlm.nih.gov/pubmed/15339393 |
|||
Target ID: CHEMBL2093863 |
0.0012 µM [IC50] | ||
Target ID: CHEMBL4729 Sources: https://www.ncbi.nlm.nih.gov/pubmed/9316851 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
The effect of selective phosphodiesterase inhibitors in comparison with other anti-asthma drugs on allergen-induced eosinophilia in guinea-pig airways. | 1995 Feb |
|
Pharmacological modulation of secondary mediator systems--cyclic AMP and cyclic GMP--on inflammatory hyperalgesia. | 1999 Jun |
|
Effects of several glucocorticosteroids and PDE4 inhibitors on increases in total lung eosinophil peroxidase (EPO) levels following either systemic or intratracheal administration in sephadex- or ovalbumin-induced inflammatory models. | 2000 Aug |
|
Anti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitro. | 2001 Apr |
|
Is up-regulation of phosphodiesterase 4 activity by PGE2 involved in the desensitization of beta-mimetics in late pregnancy human myometrium? | 2001 Nov |
|
Anti-TNF-alpha properties of new 9-benzyladenine derivatives with selective phosphodiesterase-4- inhibiting properties. | 2001 Oct 26 |
|
The selective phosphodiesterase 4 inhibitor RP 73-401 reduced matrix metalloproteinase 9 activity and transforming growth factor-beta release during acute lung injury in mice: the role of the balance between Tumor necrosis factor-alpha and interleukin-10. | 2002 Apr |
|
Phosphodiesterase isoenzyme families in human osteoarthritis chondrocytes--functional importance of phosphodiesterase 4. | 2002 Feb |
|
Potential role of phosphodiesterase 7 in human T cell function: comparative effects of two phosphodiesterase inhibitors. | 2002 Jun |
|
Essential requirements for substrate binding affinity and selectivity toward human CYP2 family enzymes. | 2003 Jan 1 |
|
Antidepressant-induced increase in high-affinity rolipram binding sites in rat brain: dependence on noradrenergic and serotonergic function. | 2003 Oct |
|
Pharmacological inhibition of phosphodiesterase 4 triggers ovulation in follicle-stimulating hormone-primed rats. | 2005 Jan |
|
Inhibition of phosphodiesterase activity, airway inflammation and hyperresponsiveness by PDE4 inhibitor and glucocorticoid in a murine model of allergic asthma. | 2006 Oct 26 |
|
Inhibition of TGF-beta induced lung fibroblast to myofibroblast conversion by phosphodiesterase inhibiting drugs and activators of soluble guanylyl cyclase. | 2007 Oct 15 |
|
Effects of phosphodiesterase inhibitors on tension induced by norepinephrine and accumulation of cyclic nucleotides in isolated human prostatic tissue. | 2008 Mar |
|
Effects of phosphodiesterase 4 inhibition on bleomycin-induced pulmonary fibrosis in mice. | 2010 May 5 |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/16875702
1, 3 and 10 mg/kg were orally administered once daily
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/8762090
RP 73401 (IC50: 6.9 +/- 3.3 nM, n = 5) was 71 fold more potent than (+/-)-rolipram (IC50: 490 +/- 260 nM, n = 4) in inhibiting LPS-induced TNF alpha release from monocytes. RP 73401 (IC50: 2 nM) was 180 fold more potent than rolipram (IC50: 360 nM) in suppressing LPS (10 ng ml-1)-induced TNF alpha mRNA.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:33:42 GMT 2023
by
admin
on
Fri Dec 15 15:33:42 GMT 2023
|
Record UNII |
WM58D7C3ZT
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C744
Created by
admin on Fri Dec 15 15:33:42 GMT 2023 , Edited by admin on Fri Dec 15 15:33:42 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
144035-83-6
Created by
admin on Fri Dec 15 15:33:42 GMT 2023 , Edited by admin on Fri Dec 15 15:33:42 GMT 2023
|
PRIMARY | |||
|
C087566
Created by
admin on Fri Dec 15 15:33:42 GMT 2023 , Edited by admin on Fri Dec 15 15:33:42 GMT 2023
|
PRIMARY | |||
|
Piclamilast
Created by
admin on Fri Dec 15 15:33:42 GMT 2023 , Edited by admin on Fri Dec 15 15:33:42 GMT 2023
|
PRIMARY | |||
|
47619
Created by
admin on Fri Dec 15 15:33:42 GMT 2023 , Edited by admin on Fri Dec 15 15:33:42 GMT 2023
|
PRIMARY | |||
|
SUB09810MIG
Created by
admin on Fri Dec 15 15:33:42 GMT 2023 , Edited by admin on Fri Dec 15 15:33:42 GMT 2023
|
PRIMARY | |||
|
II-14
Created by
admin on Fri Dec 15 15:33:42 GMT 2023 , Edited by admin on Fri Dec 15 15:33:42 GMT 2023
|
PRIMARY | |||
|
DB01791
Created by
admin on Fri Dec 15 15:33:42 GMT 2023 , Edited by admin on Fri Dec 15 15:33:42 GMT 2023
|
PRIMARY | |||
|
WM58D7C3ZT
Created by
admin on Fri Dec 15 15:33:42 GMT 2023 , Edited by admin on Fri Dec 15 15:33:42 GMT 2023
|
PRIMARY | |||
|
C96718
Created by
admin on Fri Dec 15 15:33:42 GMT 2023 , Edited by admin on Fri Dec 15 15:33:42 GMT 2023
|
PRIMARY | |||
|
DTXSID3040227
Created by
admin on Fri Dec 15 15:33:42 GMT 2023 , Edited by admin on Fri Dec 15 15:33:42 GMT 2023
|
PRIMARY | |||
|
100000082493
Created by
admin on Fri Dec 15 15:33:42 GMT 2023 , Edited by admin on Fri Dec 15 15:33:42 GMT 2023
|
PRIMARY | |||
|
154575
Created by
admin on Fri Dec 15 15:33:42 GMT 2023 , Edited by admin on Fri Dec 15 15:33:42 GMT 2023
|
PRIMARY | |||
|
CHEMBL42126
Created by
admin on Fri Dec 15 15:33:42 GMT 2023 , Edited by admin on Fri Dec 15 15:33:42 GMT 2023
|
PRIMARY | |||
|
7316
Created by
admin on Fri Dec 15 15:33:42 GMT 2023 , Edited by admin on Fri Dec 15 15:33:42 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET -> INHIBITOR |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|